JAK–STAT signalling
The relay that turns cytokine signals into gene changes. Overactive in blood cancers (JAK2 in myelofibrosis), it is also the wire that carries interferon's cancer-killing message, so tumours cut it to escape immunotherapy.
Cytokine receptors recruit JAK kinases that phosphorylate STAT transcription factors. JAK2 V617F drives myeloproliferative neoplasms (ruxolitinib, fedratinib, momelotinib approved); STAT3 is a hub for IL-6-driven survival, immunosuppression, and cachexia; STAT5 in leukaemias. Interferon-γ signalling via JAK1/2–STAT1 upregulates MHC and PD-L1; JAK1/2 loss-of-function mutations cause acquired resistance to PD-1 blockade. Direct STAT3 inhibitors (degraders, antisense) are in early trials.
In one picture
JAK–STAT is a doorbell wired to the house lights. Cytokines ring, JAK flips the switch, STAT turns on the lights. Cancers either jam the switch on (JAK2 mutation) or cut the wire so interferon cannot turn on the 'I am infected' lights.
Diagram
top- JAK inhibitors in myeloproliferative neoplasms and GVHD
- STAT3 degraders/antisense (early trials)
- Anti-IL-6 (tocilizumab) for CRS and under study for cachexia
- JAK-loss tumours: MHC-independent therapies (T-cell engagers, NK cells)
Notes
top- Leading programmes: Levine (MSK) on JAK2 and MPN; Ribas (UCLA) on JAK mutations and PD-1 resistance; Darnell legacy (Rockefeller).
Pages like this
not linked directly; found by shared links- PathwayTumour microenvironment (TME)
Shares Myeloid-derived suppressor cells (MDSCs), Inflammation & NF-κB, Myeloid suppression: TAMs, MDSCs & don't-eat-me signals, Fibroblast activation, desmoplasia & matrix stiffness and the tag mechanism.
- PathwayMicrobiome–tumour interactions
Shares Enabling characteristic: tumour-promoting inflammation, Inflammation & NF-κB, PD-1 / PD-L1 immune checkpoint & T-cell activation and the tag mechanism.
- PathwayCellular senescence
Shares Inflammation & NF-κB, Mayo Clinic, Memorial Sloan Kettering Cancer Center and the tag mechanism.
- PathwayHippo–YAP/TAZ
Shares Fibroblast activation, desmoplasia & matrix stiffness, Memorial Sloan Kettering Cancer Center and the tag mechanism.
- PathwayTGF-β signalling
Shares Fibroblast activation, desmoplasia & matrix stiffness, PD-1 / PD-L1 immune checkpoint & T-cell activation, Memorial Sloan Kettering Cancer Center and the tag mechanism.
- PathwayCircadian control
Shares PD-1 / PD-L1 immune checkpoint & T-cell activation, Memorial Sloan Kettering Cancer Center and the tag mechanism.
- PathwayClonal haematopoiesis (CHIP)
Shares Inflammation & NF-κB, Memorial Sloan Kettering Cancer Center and the tag mechanism.
- PathwayRNA splicing
Shares Antigen presentation & immune editing, Memorial Sloan Kettering Cancer Center and the tag mechanism.